Papers
Topics
Authors
Recent
2000 character limit reached

DrugMCTS: a drug repurposing framework combining multi-agent, RAG and Monte Carlo Tree Search (2507.07426v1)

Published 10 Jul 2025 in cs.AI

Abstract: Recent advances in LLMs have demonstrated considerable potential in scientific domains such as drug discovery. However, their effectiveness remains constrained when reasoning extends beyond the knowledge acquired during pretraining. Conventional approaches, such as fine-tuning or retrieval-augmented generation, face limitations in either imposing high computational overhead or failing to fully exploit structured scientific data. To overcome these challenges, we propose DrugMCTS, a novel framework that synergistically integrates RAG, multi-agent collaboration, and Monte Carlo Tree Search for drug repurposing. The framework employs five specialized agents tasked with retrieving and analyzing molecular and protein information, thereby enabling structured and iterative reasoning. Without requiring domain-specific fine-tuning, DrugMCTS empowers Qwen2.5-7B-Instruct to outperform Deepseek-R1 by over 20\%. Extensive experiments on the DrugBank and KIBA datasets demonstrate that DrugMCTS achieves substantially higher recall and robustness compared to both general-purpose LLMs and deep learning baselines. Our results highlight the importance of structured reasoning, agent-based collaboration, and feedback-driven search mechanisms in advancing LLM applications for drug discovery.

Summary

We haven't generated a summary for this paper yet.

Dice Question Streamline Icon: https://streamlinehq.com

Open Problems

We haven't generated a list of open problems mentioned in this paper yet.

Lightbulb Streamline Icon: https://streamlinehq.com

Continue Learning

We haven't generated follow-up questions for this paper yet.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

X Twitter Logo Streamline Icon: https://streamlinehq.com

Tweets

This paper has been mentioned in 1 tweet and received 0 likes.

Upgrade to Pro to view all of the tweets about this paper: